Evaluation of Clinical Impact of Interruption VS Maintenance of AI in Patients With Locally Advanced/ Metastatic Low Grade Endometrial Stromal Sarcoma (LGESS)

This trial is studying whether women with low-grade endometrial stromal sarcoma (a rare type of slow-growing uterine cancer) who have been successfully controlled on hormone-blocking drugs for at least 2–3 years should continue those drugs or can safely stop them. **You may be eligible if...** - You are 18 years or older - You have been diagnosed with low-grade endometrial stromal sarcoma - Your cancer is locally advanced, has spread to other areas, or spread during your original surgery - You have been on aromatase inhibitor therapy (such as anastrozole, exemestane, or letrozole) for at least 24–36 months - Your disease is currently controlled (stable or responding) on this therapy **You may NOT be eligible if...** - You have been on hormone-blocking therapy for less than the required duration - Your cancer is currently growing while on treatment - You are pregnant or breastfeeding Talk to your doctor to see if this trial is right for you.